Overview

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Afshin Dowlati, MD
Collaborator:
Bayer
Treatments:
Fulvestrant